Skip to main content
Clinical Trials/NCT00127673
NCT00127673
Completed
Phase 3

Effectiveness of PTSD Treatment: CBT Versus Sertraline

Case Western Reserve University1 site in 1 country200 target enrollmentSeptember 2004

Overview

Phase
Phase 3
Intervention
Cognitive behavioral therapy (CBT)
Conditions
Post-Traumatic Stress Disorder
Sponsor
Case Western Reserve University
Enrollment
200
Locations
1
Primary Endpoint
State Anxiety
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This study will compare the short- and long-term effectiveness of two different treatments for people with post-traumatic stress disorder.

Detailed Description

Exposure to traumatic events, such as automobile accidents and assault, can cause individuals to develop persistent psychological difficulties such as post-traumatic stress disorder (PTSD). PTSD is an anxiety disorder characterized by avoidance, hyperarousal symptoms, and mental re-experiencing of the traumatic event. PTSD is a serious condition that may cause social and psychological impairment; therefore, safe and effective treatments are needed. Both CBT and antidepressant therapy have been shown to effectively treat PTSD symptoms; however, comparisons of the treatments are limited. This study will compare the short- and long-term effectiveness of CBT and the antidepressant sertraline. Participants will either be randomly assigned to CBT or sertraline, or they will be able to choose one of the two treatments, which will be given for 10 weeks, followed by 24 months of follow-up assessments. Participants in the CBT group will have 10 weekly sessions of therapy. During the therapy sessions, participants will be encouraged to confront their general fears and the memory of their trauma through repeated storytelling. Participants will also be encouraged to practice the techniques learned in therapy in everyday life. Participants in the antidepressant group will take sertraline daily for 10 weeks. These participants will be seen weekly by a psychiatrist who will offer general encouragement and support, monitor response to medication, and record any side effects participants may be experiencing. The medication may be adjusted according to a dosing schedule and based on the study doctor's judgment. At the end of 10 weeks, participants in the antidepressant group will have the choice of either tapering the medication gradually to minimize the chance of withdrawal symptoms or staying on the medication for up to 24 months. Participants who do not respond to their assigned or chosen treatment will be offered the other treatment for 10 weeks. Self-report scales and questionnaires will be used to assess participants' PTSD symptoms, depression, anxiety, and social functioning. These assessments will occur at 3, 6, 12, and 24 months after the study treatment period.

Registry
clinicaltrials.gov
Start Date
September 2004
End Date
August 2011
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Norah Feeny

Professor

Case Western Reserve University

Eligibility Criteria

Inclusion Criteria

  • DSM-IV diagnosis of PTSD
  • Experienced traumatic event at least 12 weeks prior to study entry
  • Willingness to discontinue current CBT or antidepressant treatment

Exclusion Criteria

  • Current diagnosis of schizophrenia or delusional disorder
  • Medically unstable bipolar disorder, depression with psychotic features, or depression requiring psychiatric treatment
  • Current diagnosis of alcohol or substance dependence within 3 months prior to study entry
  • Ongoing intimate relationship with the perpetrator of the traumatic event
  • History of nonresponse to either CBT or sertraline
  • Medical contraindication for sertraline

Arms & Interventions

CBT no choice

Participants will receive no choice cognitive behavioral therapy (CBT no choice)

Intervention: Cognitive behavioral therapy (CBT)

CBT choice

Participants will receive choice cognitive behavioral therapy (CBT choice)

Intervention: Cognitive behavioral therapy (CBT)

sertraline no choice

Participants will receive no choice sertraline (sertraline no choice)

Intervention: Sertraline

sertraline choice

Participants will receive choice sertraline (sertraline choice)

Intervention: Sertraline

Outcomes

Primary Outcomes

State Anxiety

Time Frame: Measured at Post-Treatment, at 10 weeks

State-Trait Anxiety Inventory - State version, total score, scoring range, 0-63, with higher scores more severe

PTSD Symptoms

Time Frame: Post-treatment, ten weeks

total score, range from 0-80, higher scores are more severe

Depression Symptoms

Time Frame: Measured at Post-Treatment, at 10 weeks

Hamilton Depression Rating Scale (HAMD), total score, scoring range 0-50, with higher scores more severe depression

Secondary Outcomes

  • Quality of Life Functioning(Measured at Post-Treatment, at 10 weeks)

Study Sites (1)

Loading locations...

Similar Trials